Endocyte Newswire

Endocyte Newswire

Comprehensive Real-Time News Feed for Endocyte.

Results 1 - 20 of 60 in Endocyte

  1. Spark Investment Management LLC Has $230,000 Stake in Endocyte Inc.Read the original story w/Photo

    Monday Jan 23 | Daily Political

    Spark Investment Management LLC lowered its stake in Endocyte Inc. by 36.2% during the third quarter, Holdings Channel reports. The firm owned 74,610 shares of the biopharmaceutical company's stock after selling 42,290 shares during the period.

    Comment?

  2. Endocyte Inc. (ECYT) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Jan 19, 2017 | Daily Political

    According to Zacks, "Endocyte progress with its pipeline has been impressive. Currently, Endocyte is focused on the development of two candidates, EC1456 and EC1169, of which both are currently in early-stage studies.

    Comment?

  3. Endocyte, Inc. (ECYT) Downgraded by Zacks Investment Research to HoldRead the original story w/Photo

    Jan 18, 2017 | IntersportsWire

    According to Zacks, "Endocyte progress with its pipeline has been impressive. Currently, Endocyte is focused on the development of two candidates, EC1456 and EC1169, of which both are currently in early-stage studies.

    Comment?

  4. Insider Selling: Endocyte, Inc. (ECYT) VP Sells $59,272.20 in StockRead the original story w/Photo

    Jan 9, 2017 | IntersportsWire

    Endocyte, Inc. VP Christopher P. Leamon sold 23,244 shares of the stock in a transaction on Friday, December 30th. The stock was sold at an average price of $2.55, for a total value of $59,272.20.

    Comment?

  5. Endocyte, Inc. (ECYT) VP Sells $59,272.20 in StockRead the original story w/Photo

    Jan 4, 2017 | AmericanBankingNews.com

    Endocyte, Inc. VP Christopher P. Leamon sold 23,244 shares of the company's stock in a transaction on Friday, December 30th. The shares were sold at an average price of $2.55, for a total value of $59,272.20.

    Comment?

  6. How Anthera Pharmaceuticals Inc (ANTH) Stacks Up Against Its PeersRead the original story w/Photo

    Dec 16, 2016 | Insider Monkey

    ... examine companies such as Virtus Total Return Fund (NYSE: DCA ), Anavex Life Sciences Corp. (NASDAQ: AVXL ), and Endocyte, Inc. (NASDAQ: ECYT ) to gather more data points. At Insider Monkey, we've developed an investment strategy that has delivered ...

    Comment?

  7. How Endocyte, Inc. (ECYT) Stacks Up Against Its PeersRead the original story

    Dec 15, 2016 | Insider Monkey

    ... points. That's why we pay special attention to hedge fund activity in these stocks. Hedge fund interest in Endocyte, Inc. (NASDAQ: ECYT ) shares was flat during the third quarter. This is usually a negative indicator. 6 hedge funds that we track ...

    Comment?

  8. West Lafayette doctor saves pilota s life in ScotlandRead the original story w/Photo

    Dec 9, 2016 | WLFI-TV West Lafayette

    ... erdam. The pilot suffered a heart attack as the plane taxied to the runway. Armour is the chief medical officer for Endocyte, located in Purdue Research Park. The company also has an office in Indianapolis.

    Comment?

  9. Mission Therapeutics Appoints As ChairmanRead the original story

    Dec 4, 2016 | BioSpace

    ... He currently serves as Chairman & CEO of US based Biotech company, BlinkBio, Inc and as a Director on the boards of Endocyte Inc (NASDAQ: ECYT). He was formerly a Director at Human Genome Sciences Inc.

    Comment?

  10. Goddard named non-executive Chairman of Mission TherapeuticsRead the original story

    Dec 5, 2016 | PE Hub

    ... He currently serves as Chairman & CEO of US based Biotech company, BlinkBio, Inc and as a Director on the boards of Endocyte Inc (NASDAQ: ECYT). He was formerly a Director at Human Genome Sciences Inc. NOTES TO EDITORS: About Mission Therapeutics ...

    Comment?

  11. Mission Therapeutics logoRead the original story w/Photo

    Dec 5, 2016 | PR Newswire

    ... He currently serves as Chairman & CEO of US based Biotech company, BlinkBio, Inc and as a Director on the boards of Endocyte Inc (NASDAQ: ECYT ). He was formerly a Director at Human Genome Sciences Inc. Mission Therapeutics, an early-stage drug ...

    Comment?

  12. Endocyte Inc. (ECYT) Given Buy Rating at Credit Suisse Group AGRead the original story w/Photo

    Nov 14, 2016 | Daily Political

    They currently have a $7.00 target price on the biopharmaceutical company's stock. Separately, Zacks Investment Research upgraded shares of Endocyte from a hold rating to a buy rating and set a $3.75 target price for the company in a research note on Wednesday, October 5th.

    Comment?

  13. Wedbush Weighs in on Endocyte Inc.'s FY2016 EarningsRead the original story w/Photo

    Nov 14, 2016 | AmericanBankingNews.com

    Stock analysts at Wedbush upped their FY2016 earnings estimates for shares of Endocyte in a note issued to investors on Thursday. Wedbush analyst D. Nierengarten now anticipates that the brokerage will post earnings of per share for the year, up from their prior forecast of .

    Comment?

  14. Endocyte Inc. (ECYT) Stake Held by Eagle Global Advisors LLCRead the original story w/Photo

    Nov 12, 2016 | Daily Political

    Eagle Global Advisors LLC continued to hold its position in Endocyte Inc. during the second quarter, according to its most recent filing with the Securities and Exchange Commission . The institutional investor owned 153,160 shares of the biopharmaceutical company's stock at the end of the second quarter.

    Comment?

  15. Endocyte Inc. (ECYT) Rating Reiterated by Credit Suisse Group AGRead the original story w/Photo

    Nov 12, 2016 | AmericanBankingNews.com

    ... a potential upside of 121.52% from the company's previous close. Separately, Zacks Investment Research raised Endocyte from a "hold" rating to a "buy" rating and set a $3.75 price target for the company in a report on Wednesday, October 5th. Shares ...

    Comment?

  16. Polycystic Kidney Disease Pipeline Market Review Research for H2 2016Read the original story w/Photo

    Nov 9, 2016 | PR Newswire

    ... Pipeline Review, H2 2016 report include Angion Biomedica Corp., Aptevo Therapeutics Inc, DiscoveryBiomed, Inc., Endocyte, Inc., IC-MedTech, Inc., Ipsen S.A. , Kadmon Corporation, LLC, ManRos Therapeutics, Metabolic Solutions Development Company, ...

    Comment?

  17. Endocyte Reports Third Quarter 2016 Financial ResultsRead the original story

    Nov 9, 2016 | BioSpace

    WEST LAFAYETTE, Ind., Nov. 09, 2016 -- Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced financial results for the third quarter ending September 30, 2016, and provided a clinical and business update. "Our clinical pipeline made critical progress during the quarter as we have moved both lead SMDC product candidates, EC1456 and EC1169, into the expansion phases of their trials, and confirmed the maximum clinical doses for each," commented Mike Sherman, president and CEO at Endocyte.

    Comment?

  18. Endocyte Inc. (ECYT) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPSRead the original story w/Photo

    Nov 9, 2016 | Daily Political

    Endocyte Inc. posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported earnings per share for the quarter, topping the consensus estimate of by $0.06.

    Comment?

  19. Endocyte Announces Third Quarter 2016 Earnings Conference CallRead the original story

    Nov 2, 2016 | BioSpace

    Endocyte, Inc., announced today that the company will host a conference call on Wednesday, Nov. 9th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company's website at www.endocyte.com or by dialing 845-0711 or 298-5081 .

    Comment?

  20. Endocyte Inc. (ECYT) Scheduled to Post Quarterly Earnings on TuesdayRead the original story w/Photo

    Oct 31, 2016 | AmericanBankingNews.com

    Endocyte Inc. will announce its earnings results after the market closes on Tuesday, November 1st. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?